表紙:神経変性疾患治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
市場調査レポート
商品コード
1037048

神経変性疾患治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)

Neurodegenerative Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 147 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
神経変性疾患治療市場:世界の業界動向、シェア、規模、成長、機会、予測(2021年~2026年)
出版日: 2021年11月10日
発行: IMARC Services Private Limited
ページ情報: 英文 147 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の神経変性疾患治療の市場規模は、2015年から2020年にかけて約8%のCAGRで拡大しました。現在、患者の身体的・精神的な症状を軽減し、生活の質を向上させるために、いくつかの薬剤が使用されています。さらに、研究者たちは、神経変性疾患を早期に発見・診断し、その進行を防ぐために、分子診断法、特にバイオマーカーやイメージング分光法の開発に注力しています。

アルコールの過剰摂取による腫瘍や脳卒中の増加は、高齢者人口の増加と相まって、神経変性疾患の発症リスクを高める主な要因の一つとなっています。そのため、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症などの神経変性疾患を早期に診断するための分子診断技術の必要性が高まっています。また、さまざまな種類の神経変性疾患に対する低侵襲(MI)スクリーニング検査の開発も進められています。神経変性疾患治療の世界市場は、今後5年間で緩やかな成長を遂げると予測されています。

当レポートでは、神経変性疾患治療の世界市場について調査し、市場の概要とともに、適応別、薬剤タイプ別、投与経路別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 神経変性疾患治療の世界市場

  • 市場概要
  • 市場パフォーマンス
  • COVID-19の影響

第6章 市場セグメンテーション、適応別

  • 多発性硬化症
  • パーキンソン病
  • アルツハイマー病
  • 脊髄性筋萎縮症(SMA)
  • ハンチントン病
  • その他

第7章 市場セグメンテーション、薬剤タイプ別

  • N-メチル-D-アスパラギン酸受容体拮抗薬
  • 選択的セロトニン再取込阻害薬
  • ドーパミン阻害薬
  • その他

第8章 市場セグメンテーション、投与経路別

  • 経口
  • 注射
  • その他

第9章 市場セグメンテーション、流通チャネル別

  • 院内薬局
  • 小売薬局
  • その他

第10章 市場セグメンテーション、地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場セグメンテーション

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • キープレーヤー
  • キープレーヤーのプロファイル
    • Biogen
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A
    • Teva Pharmaceutical Industries Ltd.
    • UCB S.A
目次
Product Code: SR1020G66_Report

The global neurodegenerative disease treatment market grew at a CAGR of around 8% during 2015-2020. Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.

The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years. Looking forward, IMARC Group expects the global neurodegenerative disease treatment market to exhibit moderate growth during the next five years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global neurodegenerative disease treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, indication, drug type, route of administration and distribution channel.

Breakup by Indication:

  • Multiple Sclerosis
  • Parkinsons Disease
  • Alzheimers Disease
  • Spinal Muscular Atrophy (SMA)
  • Huntingtons Disease
  • Others

Breakup by Drug Type:

  • N-methyl-D-aspartate Receptor antagonists
  • Selective Serotonin Reuptake Inhibitors
  • Dopamine Inhibitors
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc , Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

  • How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global neurodegenerative disease treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurodegenerative Disease Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Multiple Sclerosis
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinsons Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimers Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Spinal Muscular Atrophy (SMA)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Huntingtons Disease
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 N-methyl-D-aspartate Receptor antagonists
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Selective Serotonin Reuptake Inhibitors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Dopamine Inhibitors
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Biogen
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 F. Hoffmann-La Roche AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GlaxoSmithKline Plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Novartis AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Sanofi S.A
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Teva Pharmaceutical Industries Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UCB S.A
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis